Are meaningful predictions of toxicological outcomes in clinical trials based on in vitro diagnostics of preclinical drug candidates possible?

Future Medicinal Chemistry

Volumn 2, Issue 11, 2010, Pages 1613-1617

  Kroll, Friedrich ^a   Dreger, Mathias ^a  

^a Caprotec Bioanalytics GmbH   (Germany)

Author keywords

clinical failure and success; clinical property prediction; drug protein interactions; idiosyncratic toxicity; improved drug candidates; proteomics; selectivity

Indexed keywords

ADENOSINE TRIPHOSPHATE; BIOTIN; CYTOCHROME P450; ENTACAPONE; SMALL INTERFERING RNA; TOLCAPONE;

AFFINITY CHROMATOGRAPHY; AMES TEST; CARDIOTOXICITY; COMPUTER MODEL; COVALENT BOND; CYTOTOXICITY; DRUG INDUSTRY; DRUG PROTEIN BINDING; DRUG TOXICITY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GENOMICS; GENOTOXICITY; IN VITRO STUDY; MASS SPECTROMETRY; METABOLOMICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CROSS LINKING; PROTEIN INTERACTION; PROTEIN ISOLATION; PROTEIN TARGETING; PROTEOMICS; QUALITY OF LIFE; TOXICITY TESTING;

CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; GENOMICS; HUMANS; METABOLOMICS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PROTEINS; PROTEOMICS; TOXICOLOGY; TREATMENT OUTCOME;

EID: 78649249164     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.245     Document Type: Editorial

References (21)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3(8), 711-715 (2004).
2. David E, Tramontin T, Zemmel R. Pharmaceutical R&D: the road to positive returns. Nat. Rev. Drug Discov. 8(8), 609-610 (2009).
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-ana lysis of prospective studies. JAMA 279(15), 1200-1205 (1998).
4. Gurwitz JH, Field TS, Avorn J et al. Incidence and preventability of adverse drug events in nursing homes. Am. J. Med. 109(2), 87-94 (2000).
5. Ulrich RG. Idiosyncratic toxicity: a convergence of risk factors. Ann. Rev. Med. 58, 17-34 (2007).
6. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol. 21(1), 84-92 (2008).
7. Uetrecht J. Evaluation of which reactive metabolite, if any, is responsible for a specifc idiosyncratic reaction. Drug Metabo. Rev. 38(4), 745-753 (2006).
8. Ashby J, Tennant RW. Prediction of rodent carcinogenicity for 44 chemicals: results. Mutagenesis 9(1), 7-15 (1994). (Pubitemid 24031017)
9. Baillie TA. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem. Res. Toxicol. 19(7), 889-893 (2006).
10. Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat. Biotech. 26(1), 120-126 (2008).
11. Kamiya N, Iwao E, Hiraga N et al. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor. J. Gen. Virol. 91(7), 1668-1677 (2010).
12. Li AP, Bode C, Sakai Y. A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicity of tamoxifen towards normal human cells from fve major organs and MCF-7 adenocarcinoma breast cancer cells. Chem. Biol. Interac. 150(1), 129-136 (2004).
13. Doherty MK, Hammond DE, Clague MJ, Gaskell SJ, Beynon RJ. Turnover of the human proteome: determination of protein intracellular stability by dynamic SILAC. J. Proteome Res. 8(1), 104-112 (2009).
14. Bantscheff M, Boesche M, Eberhard D, Matthieson T, Sweetman G, Kuster B. Robust and sensitive iTRAQ quantifcation on an LTQ Orbitrap mass spectrometer. Mol. Cell Proteomics, 7(9), 1702-1713 (2008).
15. Calleri E, Temporini C, Caccialanza G, Massolini G. Target-based drug discovery: the emerging success of frontal affnity chromatography coupled to mass spectrometry. ChemMedChem 4(6), 905-916 (2009).
16. Salisbury CM, Cravatt BF. Activity-based probes for proteomic profling of histone deacetylase complexes. Proc. Natl Acad. Sci. USA, 104(4), 1171-1176 (2007).
17. Koster H, Little DP, Luan P et al. Capture compound mass spectrometry: a technology for the investigation of small molecule protein interactions. Assay Drug Dev. Technol. 5(3), 381-390 (2007).
18. Fischer JJ, Michaelis S, Schrey AK et al. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two parkinson drugs. Toxicol. Sci. 113(1), 243-253 (2010).
19. Boelsterli UA, Lim PL. Mitochondrial abnormalities - a link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol. 220(1), 92-107 (2007).
20. Dykens JA, Marroquin LD, Will Y. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev. Mol. Diagn. 7(2), 161-175 (2007).
21. Dalhoff C, Huben M, Lenz T et al. Synthesis of S-adenosyl-L-homocysteine capture compounds for selective photoinduced isolation of methyltransferases. ChemBioChem 11(2), 256-265 (2010).